Company intelligence / Profile preview

EntreChem

Ownership: Private
Development stage: Other

Overview

EntreChem is developing novel, IP-protected small molecule drugs derived from natural products, with a focus on addressing multiple targets and pathways in cancer, aiming to avoid the additive toxicity of conventional chemotherapy combinations. Their lead candidates are nearing clinical trials, targeting hematologic malignancies and solid tumors with a unique polypharmacology approach[1].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

collismycin analog

Preclinical

1 more asset in the full pipeline.

Partnerships

Collaborations with leading cancer scientists in Europe and the USA

Beyond the preview

Go deeper on EntreChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EntreChem.